Join host Yumi Stynes for Seen, a new SBS podcast about cultural creatives who have risen to excellence despite a role-model ...

STAT+ subscribers can sign up here to get it delivered to their inbox. The next referendum on Gilead Sciences’ oft-criticized oncology business is approaching. Circle Nov. 5 on your calendars.

But Harvard researchers found that something much more unlikely happened when a meteorite nicknamed S2 paid a visit to our planet. Instead of ending life, the space rock may have allowed it to ...

Gilead Sciences, Inc. (GILD), headquartered in Foster City, California, is a global biopharmaceutical leader known for its groundbreaking work in antiviral therapies. Valued at a market cap of $ ...

Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Gilead Sciences (GILD – Research Report) and keeping the price target at $84.00. Terence Flynn’s rating is based on ...

The treatment combines MSD’s islatravir with Gilead’s lenacapavir. Credit: Ground Picture via Shutterstock. Gilead Sciences and MSD are advancing their once-weekly HIV treatment regimen to Phase II ...

Key Insights from Viral Hepatitis, PBC, and MASH/Fibrosis Studies Highlight Gilead’s Ongoing Commitment to Advancing Life-Changing Liver Disease Research - FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead ...

Billions of years ago, meteorites hit Earth frequently. This particular space rock, called the S2 meteorite, collided with the planet around 3.26 billion-years-ago, and after that certain life ...

Leerink has upgraded Gilead Sciences (NASDAQ:GILD) to outperform, citing the growth outlook for its PrEP treatment lenacapavir for the prevention of HIV infection. The investment firm said that ...

In the latest quarter, 15 analysts provided ratings for Gilead Sciences (NASDAQ:GILD), showcasing a mix of bullish and bearish perspectives. The following table summarizes their recent ratings ...